Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 13;38(1):300–307. doi: 10.1111/jvim.16946

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Results of (A) and (B) TK1 protein OD, and (C) and (D) TK1 autoantibody ratio (TK1 Autoantibody OD/total IgG OD) in each group and several malignant tumor groups. The TK1 autoantibody ratio showed a significant difference in the malignant tumor group compared to that in the healthy control group, nontumor disease group, or dogs with benign tumor. TK1 protein could not discriminate between group with benign tumors and group with the malignant tumors. TK1 protein was significantly higher in dogs with carcinoma including TCC, hematopoietic tumor including lymphoma, and sarcoma. TK1 autoantibody ratio was significantly higher in dogs with carcinoma including TCC and malignant MGT, hematopoietic tumor including lymphoma, and sarcoma.